3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2012 Results

Sun Mar 3, 2013 8:54am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130303:nPnCN69889


SHENYANG, China,  March 3, 2013  /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX)
("3SBio"), a leading  China-based biotechnology company focused on researching,
developing, manufacturing and marketing biopharmaceutical products, today
announced that it will release its unaudited fourth quarter and full year 2012
results on Tuesday, March 19, 2013 at  8:00am  China Standard Time.  

Following the earnings announcement, 3SBio's senior management will host a
conference call on  Tuesday, March 19, 20138:00pm  China Standard Time (8:00am 
US Eastern or  5:00am  US Pacific) to discuss its unaudited fourth quarter and
full year 2012 results and recent business activity. The conference call may be
accessed using the dial-in numbers below:

Conference ID:  15890708  

Local dial-in:
China  landline: 800-819-0121
China  mobile: 400-620-8038
Hong Kong  : 852-2475-0994
United States: 718-354-1231  

International toll-free dial-in:
Hong Kong: 800930346
United States: 1-866-519-4004
United Kingdom: 080-8234-6646

International toll dial-in:  65 6723 9381

Replay- Conference ID:  15890708
A telephone replay will be available two hours after the call until  March 27,
2013  at:
International: 61-2-8235-5000
United States: 1-866-214-5335

Webcast
A live webcast of the conference will be available on the investor relations
section of 3SBio's website at  www.3sbio.com  and at 
http://www.media-server.com/m/p/bcshv7v5.

A replay of the webcast will be available within one hour after the conclusion
of the call.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused
on researching, developing, manufacturing and marketing biopharmaceutical
products primarily in  China. Its focus is on addressing large markets with
significant unmet medical needs in nephrology, oncology, supportive cancer care,
inflammation and infectious diseases. With headquarters and GMP-certified
manufacturing facilities in  Shenyang, PRC, 3SBio employs over 800 people.
Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ
stock market under the ticker symbol "SSRX". Please see  www.3SBio.com  for more
information.

 Investor Contacts                                        
 Bo Tan                   Tom Folinsbee                   
 Chief Financial Officer  Director of Investor Relations  
 3SBio Inc.               3SBio Inc.                      
 Tel: + 86 24 2581-1820   Tel: + 852 8191-6991            
 ir@3SBio.com             ir@3SBio.com                    


SOURCE  3SBio Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.